Live Nation Entertainment, Inc. (LYV)
NYSE: LYV · Real-Time Price · USD
149.50
-1.79 (-1.18%)
Aug 5, 2025, 10:19 AM - Market open
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 19 analysts that cover Verve Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $163.95, which forecasts a 9.67% increase in the stock price over the next year. The lowest target is $133 and the highest is $185.
Price Target: $163.95 (+9.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verve Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 11 | 11 |
| Buy | 6 | 6 | 7 | 7 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 19 | 19 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $165 → $185 | Buy | Maintains | $165 → $185 | +23.75% | Jul 24, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $170 | Strong Buy | Reiterates | $170 | +13.71% | Jun 18, 2025 |
| Susquehanna | Susquehanna | Buy Maintains $155 → $165 | Buy | Maintains | $155 → $165 | +10.37% | Jun 10, 2025 |
| Wolfe Research | Wolfe Research | Buy Maintains $160 → $168 | Buy | Maintains | $160 → $168 | +12.37% | Jun 10, 2025 |
| Roth MKM | Roth MKM | Strong Buy Maintains $174 → $164 | Strong Buy | Maintains | $174 → $164 | +9.70% | May 2, 2025 |
Financial Forecast
Revenue This Year
26.18B
from 23.16B
Increased by 13.04%
Revenue Next Year
28.51B
from 26.18B
Increased by 8.92%
EPS This Year
2.17
from 2.74
Decreased by -20.63%
EPS Next Year
2.71
from 2.17
Increased by 24.82%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.5B | 31.1B | 34.0B | ||
| Avg | 26.2B | 28.5B | 31.2B | ||
| Low | 23.7B | 25.6B | 28.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.1% | 18.8% | 19.2% | ||
| Avg | 13.0% | 8.9% | 9.6% | ||
| Low | 2.5% | -2.1% | 1.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.22 | 4.15 | 5.87 | ||
| Avg | 2.17 | 2.71 | 3.76 | ||
| Low | 1.35 | 1.65 | 1.81 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 90.5% | 90.8% | 116.3% | ||
| Avg | -20.6% | 24.8% | 38.5% | ||
| Low | -50.6% | -24.3% | -33.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.